论文部分内容阅读
Lovastatin和Pravastatin为一重要的降胆固醇药,能特异性地抑制胆固醇生物合成的限速酶(HMG CoA还原酶)、向上调节(up-regulation)低密度脂蛋白受体,从而降低低密度脂蛋白水平。尽管两药的结构相似,但化学特性存在微小差异,因而导致其对HMG CoA还原酶的亲合力、药代动力学和水溶性的不同。这种差别与临床效能和耐受性之间的关系尚不清楚。本文报道了672例高胆固醇血症患者在用该两药治疗18周期间的随机、对照和双盲的研究结果。
Lovastatin and Pravastatin are important cholesterol-lowering drugs that specifically inhibit the rate-limiting enzyme of cholesterol biosynthesis (HMG CoA reductase) and up-regulate low-density lipoprotein receptors, thereby decreasing the levels of low-density lipoprotein Level. Despite the similar structure of the two drugs, there is a slight difference in chemical properties that leads to their differences in affinity, pharmacokinetics and water solubility of the HMG CoA reductase. The relationship between this difference and clinical efficacy and tolerability is not clear. This article reports the results of a randomized, controlled, double-blind study of 672 patients with hypercholesterolemia who were treated with the two drugs for 18 weeks.